17 Sept EMA CHMP recommended marketing authorisation for secukinumab (Cosentyx) in the treatment of polymyalgia rheumatica. BUT- not yet EMA approved in the EU. https://t.co/ZGUSbw06vX https://t.co/EqRwpT8Sxo
Links:
Cosentyx - opinion on variation to marketing authorisation | European Medicines…
https://buff.ly/zKvrVgD
Sep-21-2026
